Barclays PLC Raises Stock Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

Barclays PLC boosted its holdings in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 126.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 318,910 shares of the company's stock after purchasing an additional 178,179 shares during the quarter. Barclays PLC owned about 0.14% of Sana Biotechnology worth $1,325,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. FMR LLC raised its holdings in shares of Sana Biotechnology by 16.3% in the third quarter. FMR LLC now owns 31,609,175 shares of the company's stock valued at $131,494,000 after buying an additional 4,438,949 shares during the last quarter. Geode Capital Management LLC raised its stake in Sana Biotechnology by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company's stock valued at $13,175,000 after acquiring an additional 276,055 shares during the last quarter. State Street Corp lifted its position in Sana Biotechnology by 4.2% during the 3rd quarter. State Street Corp now owns 6,627,320 shares of the company's stock worth $27,570,000 after acquiring an additional 269,274 shares during the period. Integral Health Asset Management LLC grew its stake in shares of Sana Biotechnology by 22.4% in the 2nd quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company's stock valued at $6,552,000 after purchasing an additional 220,000 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Sana Biotechnology by 11.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,047,846 shares of the company's stock valued at $4,359,000 after purchasing an additional 105,382 shares during the period. Institutional investors and hedge funds own 88.23% of the company's stock.

Sana Biotechnology Trading Down 14.9 %

SANA stock opened at $3.66 on Monday. Sana Biotechnology, Inc. has a 52 week low of $1.52 and a 52 week high of $12.00. The company has a market cap of $817.16 million, a P/E ratio of -2.61 and a beta of 1.45. The company's 50-day moving average price is $2.40 and its 200 day moving average price is $4.04.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. On average, equities research analysts expect that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Insider Buying and Selling at Sana Biotechnology

In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of the company's stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the sale, the insider now owns 4,541,511 shares of the company's stock, valued at $29,474,406.39. This represents a 6.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 31.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on SANA. JMP Securities lowered shares of Sana Biotechnology from an "outperform" rating to a "market perform" rating in a research report on Tuesday, November 5th. TD Cowen upgraded shares of Sana Biotechnology from a "hold" rating to a "buy" rating in a research note on Wednesday, January 8th. Finally, HC Wainwright lifted their price objective on Sana Biotechnology from $8.00 to $11.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Sana Biotechnology has an average rating of "Moderate Buy" and a consensus price target of $14.25.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.